Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines

Who May Be Eligible (Plain English)

Who May Qualify: - ● Aged ≥18 years. - SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. - Patients cooperative and can answer questions. - Patients who are able and willing to give written willing to sign a consent form Who Should NOT Join This Trial: - ● Individuals with other autoimmune conditions (where your immune system attacks your own body)s. - Patients receive any hyperuricemia treatment - Pregnancy - Malignancy - Diabetes. - Hypertension. - Heart failure. - Hepatic diseases. - Chronic renal failure other than lupus nephritis. - Renal artery stenosis. - Renal vein thrombosis. - Intrarenal arteriovenous fistula. - Obstructive nephropathy. - Urinary tract obstruction that could affect RI of intra renal arteries. - Uncooperative patients. - Patients not able and willing to give written willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * ● Aged ≥18 years. * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. * Patients cooperative and can answer questions. * Patients who are able and willing to give written informed consent Exclusion Criteria: * ● Individuals with other autoimmune diseases. * Patients receive any hyperuricemia treatment * Pregnancy * Malignancy * Diabetes. * Hypertension. * Heart failure. * Hepatic diseases. * Chronic renal failure other than lupus nephritis. * Renal artery stenosis. * Renal vein thrombosis. * Intrarenal arteriovenous fistula. * Obstructive nephropathy. * Urinary tract obstruction that could affect RI of intra renal arteries. * Uncooperative patients. * Patients not able and willing to give written informed consent.

Treatments Being Tested

DIAGNOSTIC_TEST

interleukin- 17

focused on the importance of IL-17 in SLE, and its relation to different disease activity

Locations (1)

Sohag university Hospital
Sohag, Egypt